Dulaglutide Research Guide

Full name: Dulaglutide (Trulicity)

A long-acting GLP-1 receptor agonist consisting of a GLP-1 analog fused to an IgG4 Fc domain. Approved for type 2 diabetes and shown to produce significant weight loss. Once-weekly dosing makes it convenient for adherence.

How Dulaglutide Works

Activates GLP-1 receptors in pancreatic beta cells (enhancing glucose-dependent insulin secretion), the hypothalamus (reducing appetite), and the GI tract (slowing gastric emptying). The Fc fusion extends half-life to ~5 days.

Dosing Protocol

• Typical dose: 0.75 mg - 4.5 mg once weekly
• Frequency: Once weekly
• Duration: Ongoing (chronic treatment)
• Route: Subcutaneous injection (pre-filled pen)

Reported Benefits

• Significant weight loss (3-5% at standard doses)
• Improved glycemic control
• Reduced cardiovascular events (REWIND trial)
• Once-weekly convenience
• Appetite suppression

Potential Side Effects

• Nausea (most common, usually transient)
• Diarrhea
• Vomiting
• Decreased appetite
• Injection site reactions
• Rare: pancreatitis risk

Research Citations

1. AWARD clinical trial program (2017) - Dulaglutide demonstrated superior A1c reduction vs placebo and non-inferiority to insulin glargine across multiple trials.
2. REWIND cardiovascular outcomes (2019) - Dulaglutide reduced major cardiovascular events (MACE) by 12% vs placebo in 9,901 patients over median 5.4 years.
3. Dulaglutide weight effects in non-diabetics (2021) - 4.5 mg dose produced 4.7% weight loss at 36 weeks in overweight/obese adults without diabetes.

Related Weight Management Compounds

• AOD-9604 - Full Profile
• Semaglutide - Full Profile
• Tirzepatide - Full Profile
• Retatrutide - Full Profile
• Tesofensine - Full Profile
• CagriSema - Full Profile

View full Dulaglutide profile with 3D molecule viewer →